Unibest

Pharmaceutical intermediates

Brigatinib Intermediates

4 pharmaceutical intermediates for Brigatinib. Indication: Non-small cell lung cancer.

Submit a ProjectAll intermediates

About Brigatinib

Originator
Ariad Pharmaceuticals Inc
Indication
Non-small cell lung cancer
Approved Date
10/02/2017
DS/DP
05/21/2019

Available intermediates

4 intermediates currently listed for Brigatinib. Request specifications, documentation or a quotation for any item below.

Brigatinib intermediates
Product NameCAS No.Molecular FormulaPhysical Properties
2-(Dimethylphosphinyl)benzenamine1197953-47-1//
2,5-Dichloro-N-[2-(dimethylphosphinyl)phenyl] -4-pyrimidinamine1197953-49-3//
2-Methoxy-4-[4-(4-methylpiperazin -1-yl)piperidin-1-yl]aniline761440-75-9//
1-Methyl-4-(4-piperidyl)piperazine Dihydrochloride;1 -Methyl-4- (piperidin-4-yl)1219979-73-3//

Other programs under B

Baloxavir MarboxilBaricitinibBDTX-1535Bedaquiline FumarateBelumosudil mesylateBelzutifanBempedoic acidBeraprost Sodium

Building toward Brigatinib?

Tell us the step you need covered and the specification you are filing against. We will confirm supply, documentation and lead time.

Submit a Project Talk to the team

How can we help you?

Receive insights into the latest events and regulatory updates

Sent directly to your email

Get industry insights and Unibest news here

Contact Us →